● “Unraveling the hidden possibilities of two-dimensional mapping: Visualized similarities between genes of interest and diseases/symptoms”
Researchers keep up to date with the latest information and repeatedly imagine and verify relationships between genes or genes and diseases. However, it is not easy to connect all the information and imagine its relationships comprehensively and comprehensively. Our unique natural language processing AI engine "KIBIT" learns currently known information and comprehensively presents relationships, including possibilities beyond that, in a comprehensive and bird's-eye view.
In this seminar, we will discuss a method to comprehensively and comprehensively search for optimally adapted diseases that can be targeted by genes of interest, using two-dimensional mapping created with "KIBIT" that visualizes the similarity between genes of interest and diseases/symptoms. I will introduce this with specific examples.

● “AI drug discovery research support solution specialized for hypothesis generation”
It is currently extremely difficult for drug discovery researchers to discover target molecules with unreported association with disease. At the FRONTEO Drug Discovery AI Factory, biologists who have extensive drug discovery experience cultivated at major pharmaceutical companies and international research institutes and a deep understanding of AI utilize in-house developed natural language processing AI and use their own analysis methods.By using this, it has become possible to propose multiple highly novel target genes and their hypotheses in a short period of time.
We will introduce support for significantly improving the efficiency, acceleration, and success rate of drug discovery research through the fusion of AI and biologists.

[Date and time] January 2024, 1 (Friday) 26:12~00:13

[Format] Online (Zoom Webinars)

[Participation conditions]
We kindly ask that you refrain from applying if you are using the free address, if you are in the same industry as us, or if you do not know your affiliation.When accessing Zoom on the day, please enter your name and email address that you entered at the time of application in the entry field for Zoom participation.

FRONTEO Inc.
Executive Officer CTO Drug Discovery AI Factory Executive Officer
Director of Neurolinguistics Research Institute Director of Behavioral Informatics Research Institute
Ph.D. (Science)
Hiroyoshi Toyoshiba

Waseda University Graduate School of Science and Engineering Department of Mathematics.Since 2000, during the doctoral course in science (mathematics, obtained a doctorate in 1999), he has been in charge of statistical analysis of medical data at the Medical Information Department of Kyushu University Hospital. Since 2000, he has participated in research on carcinogenic processes by data analysis at the National Institute of Environmental Health Sciences (NIEHS). Since 2004, he has been engaged in statistical analysis of toxicity data, design of epidemiological research, and data analysis research at the National Institute for Environmental Studies. Joined Takeda Pharmaceutical Company Limited in 2006, and has served as a researcher in the field of bioinformatics, head of the Global Data Science Institute / Japan Site Bioinformatics, and a science fellow.He is also involved in gene expression data analysis and target search in clinical trial data, as well as biomarker search in immunity and cancer.
Engaged in life science AI development at FRONTEO since 2017.He develops AI algorithms specialized in the area of ​​life sciences.Utilizing the feature of vectorization of text, we have developed various AI products based on this artificial intelligence, such as research paper search, drug discovery support, dementia diagnosis support, and fall prediction.
Life Science AI CTO since 2019. In 2021, he will be appointed as an executive officer.Further promote the social implementation of AI through a mathematical approach.

FRONTEO Inc.
Life Science AI Business Division Life Science AI Research Team 
Kiyoko Takahashi

After graduating from Tokyo University of Science Graduate School, joined Taisho Pharmaceutical Co., Ltd. He is engaged in pharmacological research for drug discovery in the fields of immunity and infectious diseases. Currently, he is in charge of analysis and hypothesis generation using Drug Discovery Best Known Methods (DD-BKM).​